Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUPHNASDAQ:GYRENASDAQ:MLYSNYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUPHAurinia Pharmaceuticals$8.15+0.9%$8.01$5.11▼$10.67$1.10B1.161.33 million shs1.49 million shsGYREGyre Therapeutics$10.18+17.3%$8.97$6.11▼$19.00$813.82M1.9112,089 shs1.98 million shsMLYSMineralys Therapeutics$15.73-1.4%$14.45$8.24▼$18.38$1.03B-0.3487,257 shs946,814 shsPBHPrestige Consumer Healthcare$85.81+0.1%$83.59$62.35▼$90.04$4.24B0.44297,868 shs296,398 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUPHAurinia Pharmaceuticals+0.87%-1.81%-0.37%+2.52%+56.43%GYREGyre Therapeutics+17.28%-10.70%+12.24%-11.56%-15.10%MLYSMineralys Therapeutics-1.44%-2.30%+17.92%+62.50%+28.93%PBHPrestige Consumer Healthcare-0.20%-1.99%+6.56%-0.53%+34.13%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUPHAurinia Pharmaceuticals3.0609 of 5 stars3.51.00.00.04.11.71.9GYREGyre Therapeutics0.3025 of 5 stars0.02.00.00.02.41.70.0MLYSMineralys Therapeutics2.9279 of 5 stars3.51.00.00.04.15.00.0PBHPrestige Consumer Healthcare3.7426 of 5 stars1.33.01.73.53.12.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUPHAurinia Pharmaceuticals 3.00Buy$11.5041.10% UpsideGYREGyre Therapeutics 3.00BuyN/AN/AMLYSMineralys Therapeutics 3.00Buy$38.00141.58% UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.338.77% UpsideCurrent Analyst Ratings BreakdownLatest PBH, AUPH, GYRE, and MLYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025MLYSMineralys TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$48.005/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold4/2/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.00 ➝ $42.003/21/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.003/11/2025GYREGyre TherapeuticsNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform3/10/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUPHAurinia Pharmaceuticals$247.30M4.45N/AN/A$2.63 per share3.10GYREGyre Therapeutics$100.64M9.48$0.20 per share50.49$0.18 per share56.56MLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/APBHPrestige Consumer Healthcare$1.14B3.73$5.04 per share17.03$36.10 per share2.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUPHAurinia Pharmaceuticals-$78.02M$0.28N/A14.55N/A-10.23%-4.41%-3.07%8/7/2025 (Estimated)GYREGyre Therapeutics-$92.93M$0.02509.00∞N/A-84.57%-118.43%-71.97%8/12/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.73N/AN/AN/AN/A-67.97%-62.40%8/12/2025 (Estimated)PBHPrestige Consumer Healthcare$209.34M$4.2920.0918.032.6919.13%12.36%6.39%8/14/2025 (Estimated)Latest PBH, AUPH, GYRE, and MLYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AUPHAurinia Pharmaceuticals$0.08$0.16+$0.08$0.16$61.06 million$62.47 million5/12/2025Q1 2025MLYSMineralys Therapeutics-$1.02-$0.79+$0.23-$0.79N/AN/A5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million3/17/2025Q4 2024GYREGyre Therapeutics$0.04$0.01-$0.03$0.02$23.50 million$27.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUPHAurinia PharmaceuticalsN/AN/AN/AN/AN/AGYREGyre TherapeuticsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.21%N/A44.29%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUPHAurinia Pharmaceuticals0.175.605.11GYREGyre TherapeuticsN/A3.723.29MLYSMineralys TherapeuticsN/A14.0214.02PBHPrestige Consumer Healthcare0.563.682.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUPHAurinia Pharmaceuticals36.83%GYREGyre Therapeutics23.99%MLYSMineralys Therapeutics84.46%PBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipAUPHAurinia Pharmaceuticals12.20%GYREGyre Therapeutics19.52%MLYSMineralys Therapeutics25.56%PBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUPHAurinia Pharmaceuticals300135.10 million137.02 millionOptionableGYREGyre Therapeutics4093.76 million75.27 millionNo DataMLYSMineralys Therapeutics2865.18 million33.27 millionOptionablePBHPrestige Consumer Healthcare54049.42 million48.75 millionOptionablePBH, AUPH, GYRE, and MLYS HeadlinesRecent News About These CompaniesTwo Sigma Investments LP Has $6.50 Million Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 28 at 4:09 AM | marketbeat.comPrestige Consumer Gains 35.7% in a Year: What's Driving the Stock?May 27 at 9:15 AM | zacks.com1,087,620 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Bought by Kayne Anderson Rudnick Investment Management LLCMay 27 at 5:54 AM | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Decreased by Nuveen Asset Management LLCMay 27 at 3:53 AM | marketbeat.comNorth Star Asset Management Inc. Cuts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 26 at 6:16 AM | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 25 at 4:03 AM | marketbeat.comFocus Partners Wealth Acquires Shares of 3,015 Prestige Consumer Healthcare Inc. (NYSE:PBH)May 25 at 3:37 AM | marketbeat.comDeutsche Bank AG Purchases 14,929 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)May 23, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Position Reduced by Ameriprise Financial Inc.May 23, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Westwood Holdings Group Inc.May 21, 2025 | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Upgraded to "Buy" at StockNews.comMay 19, 2025 | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Raised to Buy at StockNews.comMay 19, 2025 | americanbankingnews.comLazard Asset Management LLC Raises Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $10.94 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 17, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Stake Increased by Bank of America Corp DEMay 17, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Jane Street Group LLCMay 17, 2025 | marketbeat.comPBH vs. ESLOY: Which Stock Should Value Investors Buy Now?May 14, 2025 | zacks.comPrestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin IncreaseMay 13, 2025 | finance.yahoo.comSusquehanna International Group LLP Increases Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 13, 2025 | marketbeat.comQ1 Earnings Forecast for PBH Issued By William BlairMay 13, 2025 | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Posts Earnings Results, Beats Expectations By $0.02 EPSMay 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePBH, AUPH, GYRE, and MLYS Company DescriptionsAurinia Pharmaceuticals NASDAQ:AUPH$8.15 +0.07 (+0.87%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$8.36 +0.21 (+2.52%) As of 08:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.Gyre Therapeutics NASDAQ:GYRE$10.18 +1.50 (+17.28%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$10.20 +0.02 (+0.15%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Mineralys Therapeutics NASDAQ:MLYS$15.73 -0.23 (-1.44%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$16.18 +0.45 (+2.89%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Prestige Consumer Healthcare NYSE:PBH$85.80 +0.06 (+0.06%) Closing price 05/27/2025 03:59 PM EasternExtended Trading$85.87 +0.07 (+0.08%) As of 05/27/2025 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Advance Auto Parts: Did Earnings Defuse Tariff Concerns? Apple Sinks After New 25% Tariff Announcement—What's The Bottom? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
